Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective
Source: Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Video

Now Playing...
Review the mechanism of action for immune checkpoint inhibitors, the rationale and data supporting their use in HCC, and key issues and controversies around moving this new class of agents into the clinic from the live satellite symposium at AASLD 2016. (109 minutes).

Ghassan K. Abou-Alfa, MD, has disclosed that he and/or his spouse have received consulting fees from Aduro, Agios, Array, Aslan, Astellas Pharma US, Bayer, Blueprint Medicines, Boston Scientific, Bristol-Myers Squibb, Celgene, CASI, Celsion, Delcath, Eisai, EMD Serono, Gilead Sciences, Halozyme, IntegraGen, Ipsen, Janssen, Merck, Merrimack, Momenta, New B Innovation, NewLink Genetics, Onxeo, Opsona, Pfizer, Roche, sanofi-aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus, and Westhaven and funds for research support from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, CASI, Celgene, Chugai, Exelixis, Genentech, Incyte, Lilly, MabVax, MedImmune, Momenta, Myriad Genetics, OncoMed, Polaris, Roche, and Vicus.

Osama E. Rahma, MD, has disclosed that he has received research funding from Merck.

Tamar Taddei, MD, has disclosed that she has received consulting fees and funds for research support from Bayer.

Andrew X. Zhu, MD, PhD, FACP, has disclosed that he has received consulting fees from Bristol Myers-Squibb, Eisai, Merck, Nimbus, Novartis, Onkaido, and sanofi-aventis and funds for research support from Lilly.

Downloads

  • Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective